Cover Image

Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial

Purpose - PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by...

Full description

Saved in:
Bibliographic Details
Main Authors: Hennerici, Michael G. (Author) , Bots, Michiel L. (Author) , Ford, Ian (Author) , Laurent, Stéphane (Author) , Touboul, Pierre Jean (Author)
Format: Article (Journal)
Language:English
Published: 20 May 2010
In: Cardiovascular drugs and therapy
Year: 2010, Volume: 24, Issue: 2, Pages: 175-180
ISSN:1573-7241
DOI:10.1007/s10557-010-6231-2
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s10557-010-6231-2
Verlag, lizenzpflichtig, Volltext: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887499/
Get full text
Author Notes:Michael G. Hennerici, Michiel L. Bots, Ian Ford, Stéphane Laurent, Pierre Jean Touboul
Description
Summary:Purpose - PERFORM is exploring the efficacy of terutroban versus aspirin for secondary prevention in patients with a history of ischemic stroke or transient ischemic attacks (TIAs). The PERFORM Vascular Project will evaluate the effect of terutroban on progression of atherosclerosis, as assessed by change in carotid intima-media thickness (CIMT) in a subgroup of patients. - - Methods and results - The Vascular Project includes structural (CIMT, carotid plaques) and functional (carotid stiffness) vascular studies in all patients showing at least one carotid plaque at entry. Expected mean follow-up is 36 months. Primary endpoint is rate of change of CIMT. Secondary endpoints include emergent plaques and assessment of carotid stiffness. 1,100 patients are required for 90% statistical power to detect treatment-related CIMT difference of 0.025 mm. The first patient was randomized in April 2006. - - Conclusions - The PERFORM Vascular Project will investigate terutroban’s effect on vascular structure and function in patients with a history of ischemic stroke or TIAs.
Item Description:Gesehen am 12.03.2021
Physical Description:Online Resource
ISSN:1573-7241
DOI:10.1007/s10557-010-6231-2

Similar Items